A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification
European Journal of Cancer2017Vol. 87, pp. 131–139
Citations Over TimeTop 10% of 2017 papers
Eric Angevin, Gianluca Spitaleri, Jordi Rodón, Katia Dotti, Nicolás Isambert, Stefania Salvagni, Víctor Moreno, Sylvie Assadourian, Corinne Gomez, Marzia Harnois, Antoine Hollebecque, Analía Azaro, Alice Hervieu, Karim Rihawi, Filippo de Marinis
Abstract
NCT01391533.
Related Papers
- → Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma(2011)272 cited
- → Comparison of Different Tumor Response Criteria in Patients with Hepatocellular Carcinoma After Systemic Therapy with the Multikinase Inhibitor Sorafenib(2010)29 cited
- → The RECIST criteria compared to conventional response evaluation after peptide receptor radionuclide therapy in patients with neuroendocrine neoplasms(2018)9 cited
- → Comparison of response evaluation criteria in solid tumors (RECIST), European Association for the study of the liver (EASL) and modified RECIST criteria in evaluation of tumor response after transarteriai chemoembolization of primary liver cancer(2011)2 cited
- → Application of circulating tumor cells detection in chemotherapeutic efficacy evaluation of non-small cell lung cancer(2018)